|
Patient Characteristics
|
N (%)
|
|---|
|
Age (years), Median (range)
|
53 (39–76)
|
|
Sex
|
|
Male
|
5 (63)
|
|
Female
|
3 (37)
|
|
Race
|
|
White
|
7 (88)
|
|
Black
|
1 (12)
|
|
Histology
|
|
Thymoma
|
7 (88)
|
|
B1
|
1
|
|
B2
|
3
|
|
B3
|
3
|
|
Thymic carcinoma
|
1 (12)
|
|
Stage at presentation
|
|
IVA
|
1 (12)
|
|
IVB
|
7 (88)
|
|
Previous treatment
|
|
Systemic therapya, Median (range)
|
3.5 (2–10)
|
|
Thymectomyb
|
7 (88)
|
|
Chest radiation therapy
|
7 (88)
|
- a Includes: Cisplatin + Doxorubicin + Cyclophosphamide (PAC), PAC + Prednisone, PAC + Belinostat, Cisplatin + Etoposide, Carboplatin + Etoposide, Carboplatin + Paclitaxel, Gemcitabine + Capecitabine, Cisplatin, Paclitaxel, Gemcitabine, Pemetrexed, Sunitinib, Cixutumumab, Milciclib, Octreotide, Amrubicin, Saracatinib, and Belinostat. bIncludes one case of debulking surgery
